================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------
FORM 8-K
-------------
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 26, 2004
Keryx Biopharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware 000-30929 13-4087132
(State or other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
750 Lexington Avenue
New York, New York 10022
(Address of principal executive offices)
(212) 531-5965
(Registrant's telephone number, including area code)
================================================================================
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits
The following exhibit is filed as a part of this report:
Exhibit
Number Description
------ -----------
99.1 Press Release dated March 26, 2004.
Item 12. Results of Operations and Financial Condition
On March 26, 2004, Keryx Biopharmaceuticals, Inc. ("Keryx") issued a press
release announcing results of operations for the fourth quarter and year ended
December 31, 2003. Keryx also announced that it would host a conference call on
March 26, 2004 for investors where Keryx will discuss its results of operations
and financial results. A copy of such press release is attached to this current
report on Form 8-K as Exhibit 99.1 and is being furnished under Item 12 of Form
8-K.
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Keryx Biopharmaceuticals, Inc.
(Registrant)
Date: March 26, 2004
By: /s/ Ron Bentsur
-----------------------------
Ron Bentsur
Vice President - Finance
and Investor Relations
-3-
INDEX TO EXHIBITS
Exhibit
Number Description
------ -----------
99.1 Press Release dated March 26, 2004.
-4-